An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

• Status: Terminated
• Trial end date: 2018-08-28
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Nivolumab

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per RECIST v1.1

• Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting if such a therapy exists

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

• Ability to swallow tablets

• Adequate bone marrow and organ function, as defined by the protocol

Exclusion Criteria:

• Participants with known or suspected CNS metastases, untreated CNS metastases, or with the CNS as the only site of disease (patients with controlled brain metastasis allowed to enroll)

• Ocular melanoma

• Any significant acute or chronic medical illness

• Prior malignancy

• Other active malignancy requiring concurrent intervention

• Prior organ allograft or allogeneic bone marrow transplantation

• Participants with active, known, or suspected autoimmune disease

• Requirement for daily supplemental oxygen

• Uncontrolled or significant cardiovascular disease

• Pre-existing liver disease

• Gastrointestinal disease known to interfere with absorption

Other protocol defined inclusion/exclusion criteria could apply